European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk-Reference-Cited by-同舟云学术

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Published:2016-10-27 Issue: Volume: Page:ehw480
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:Eur Heart J

Author:

Landmesser Ulf,John Chapman M.,Farnier Michel,Gencer Baris,Gielen Stephan,Hovingh G. Kees,Lüscher Thomas F.,Sinning David,Tokgözoğlu Lale,Wiklund Olov,Zamorano Jose Luis,Pinto Fausto J.,Catapano Alberico L.,

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/38/29/2245/19377893/ehw480.pdf

Reference56 articles.

1. Economic burden of cardiovascular diseases in the enlarged European Union

2. Acute and chronic impact of cardiovascular events on health state utilities

3. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

4. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

5. Catapano AL Graham I De Backer G Wiklund O Chapman MJ Drexel H Hoes AW Jennings CS Landmesser U Pedersen TR Reiner Ž Riccardi G Taskinen MR Tokgozoglu L Verschuren WM Vlachopoulos C Wood DA Zamorano JL ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; pii: ehw272. [Epub ahead of print].

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat;American Journal of Cardiovascular Drugs;2024-05-23

2. First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population;Clinical Therapeutics;2024-03

3. Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy;International Journal of Molecular Sciences;2024-01-29

4. Current Status and Principles for the Treatment and Prevention of Diabetic Foot Ulcers in the Cardiovascular Patient Population: A Scientific Statement From the American Heart Association;Circulation;2024-01-23

5. Disorders of lipid metabolism. Clinical Guidelines 2023;Russian Journal of Cardiology;2023-06-03